RICT 2018

CALL FOR ABSTRACTS

Deadline: May 15, 2018

Register and Submit your abstract

Conferences > Upcoming events > RICT 2018
Wednesday July 4, 2018
07:30Registration
08:30Opening and Inaugural Lecture
09:00PL01 - Disrupting Cancer Care & Outcomes by Putting Patients in the Driving Seat
Dr Anne BRUINVELS
(PX HEALTHCARE, London, United Kingdom)
Session 1 - New Breakthrough in GPCR Structure, Function and Drug Discovery
09:45PL02 - Novel Modes of Chemical Regulation of GPCRs
Prof. Graeme MILLIGAN
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)
10:30Coffee break and Exhibition
11:00PL03 - Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism
Dr Patrick SCHNIDER
(ROCHE PHARMACEUTICAL, Basel, Switzerland)
11:45PL04 - Ghrelin Receptor Ligands: from the Bench to the Drug!
Dr Jean-Alain FEHRENTZ
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)
12:30Lunch
13:00Poster session and Exhibition
14:30PL05 - Structure-Based Drug Discovery for G Protein-Coupled Purine Receptors
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
15:15PL06 - Structure-guided Development of Selective GPCR Ligands
Prof. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)
16:00Coffee break and Exhibition
Session 2 - Novel Synthetic Methods For Therapeutic Innovation
16:30PL07 - Late Stage Fluorination for Medicine
Prof. Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
17:15PL08 - Single Electron Processes Enabling Organic Synthesis
Prof. Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)
18:00Welcome and networking reception
Thursday July 5, 2018
08:30PL09 - Paul Ehrlich Award Lecture - Chemical Biology on the Genome
Prof. Shankar BALASUBRAMANIAN
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
Session 3 - Biologically Active Chemical SpaceSession 4 - Chemokine Targeted Drug Discovery
09:30PL10 - Ancient and Modern Scaffolds for Biologically Active Chemical Space
Prof. Arasu GANESAN
(UNIVERSITY OF EAST ANGLIA, Norwich, United Kingdom)
PL11 - Decoy Chemokine Ligands Targeting CXCL12, CCL17 and CCL22: Discovery and Anti-inflammatory Activity
Dr Jean-Luc GALZI
(CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France)
10:15Coffee break and Exhibition
Session 5 - Advances in GPCR drug discoverySession 6 - Advances in Biological Imaging
11:00KL01 - Discovery of The Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure
Dr Carsten SCHMECK
(BAYER, Wuppertal, Germany)
KL03 - Dye-loaded Lipid Nanoparticles: Contrast Agents for Image-guided Surgery and Tools for Drug Delivery
Dr Isabelle TEXIER
(LETI-HEALTH, Grenoble, France)
11:30KL02 - Discovery of New Brain Penetrating Neuropeptide S Receptor (Npsr) Antagonists
Dr Julien POTHIER
(IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland)
KL04 - Inducible Chemical-genetic Fluorescent Markers for Bioimaging
Dr Arnaud GAUTIER
(ECOLE NORMALE SUPÉRIEURE, Paris, France)
12:00Lunch
12:30Poster session and Exhibition
Session 7 - Challenging Targets and Approaches Session 8 - Understanding Binding Characteristics
14:00PL12 - Discovery of Foliglurax, an mGluR4 PAM for the Treatment of Parkinson’s Disease.
Dr Stephan SCHANN
(DOMAIN THERAPEUTICS SA, Illkirch, France)
PL14 - Pharmacophore-based Analysis of Molecular Dynamics Trajectories: Towards Understanding KD of Protein Ligands
Prof. Thierry LANGER
(UNIVERSITY OF VIENNA, Vienna, Austria)
14:45PL13 - Potential Therapeutic Targets in the Brain Renin-Agiotensin and Apelinergic Systems for Treatment of Cardiovascular Diseases
Dr Catherine LLORENS-CORTES
(INSERM-COLLÈGE DE FRANCE, Paris, France)
PL15 - Identifying Inter-Helical Interactions Involved in GPCR Structure-Function and the Forces that Determine Receptor-Ligand Residence Time
Dr Alexander HEIFETZ
(EVOTEC, Abingdon, United Kingdom)
15:30KL05 - Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering
Dr Julie CHARTON
(UNIVERSITY OF LILLE, INSTITUT PASTEUR DE LILLE, Lille, France)
KL06 - Drug-target Residence Time – a Misleading Concept
Dr Rutger FOLMER
(MERCACHEM, Nijmegen, The Netherlands)
16:00Coffee break and Exhibition
Session 9 - Tackling Challenges in Drug DeliverySession 10 - Chemistry Driven Biological Exploration
16:30PL16 - Cellular Delivery and Oral Uptake of Cyclic Peptides
Dr Thomas VORHERR
(NOVARTIS, Basel, Switzerland)
PL18 - Chemistry as the Helping Tool to Develop New Therapeutic Strategies
Prof. Maria Luz LOPEZ-RODRIGUEZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)
17:15PL17 - Nanoparticle-based Strategies in Oncology
Prof. Jean-Pierre BENOIT
(UNIVERSITY OF ANGERS, Angers, France)
PL19 - Chemical Tools to Probe Reversible Lysine Acetylation
Prof. Manfred JUNG
(ALBERT LUDWIGS UNIVERSITY OF FREIBURG, Freiburg, Germany)
Friday July 6, 2018
Session 11 - New modalities in Drug Discovery
08:30PL20 - PROTAC-mediated Protein Degradation: A New Therapeutic Modality
Prof. Craig CREWS
(UNIVERSITY OF YALE, New Haven, United States)
09:15PL21 - The Confobody technology, a New Platform to Enable Fragment Screening on GPCRs
Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium)
10:00Coffee break and Exhibition
Session 12 - Chemistry in Living Systems
10:30PL22 - Two Adventures in Chemical Biology - in vivo chemistry and real-time optical medical imaging.
Prof. Mark BRADLEY
(UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom)
11:15PL23 - Therapeutic In Vivo Synthetic Chemistry
Prof. Nori TANAKA
(RIKEN, Saitama, Japan)
12:00PL24 - Pierre Fabre Award lecture
13:00Concluding remarks

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys